Dr. Kharfan Dabaja is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4500 San Pablo Rd S
Jacksonville, FL 32224Phone+1 904-953-2000
Education & Training
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 1999 - 2002
Good Samaritan Hospital of MarylandResidency, Internal Medicine, 1996 - 1999
American University of Beirut Faculty of MedicineClass of 1995
Certifications & Licensure
FL State Medical License 2005 - 2026
IN State Medical License 2001 - 2025
OK State Medical License 2002 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide.Anmol Baranwal, Kimberly J Langer, Mohamed A Kharfan-Dabaja, Ernesto Ayala, James Foran
Transplantation and Cellular Therapy. 2025-01-01 - Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations ...Mohamed Amine Bekadja, Dietger Niederwiser, Mohamed A Kharfan-Dabaja, Riad El Fakih, Laurent Garderet
Bone Marrow Transplantation. 2025-01-01 - Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1.Yan Luo, Martha E Gadd, Yaqing Qie, Andrea Otamendi-Lopez, Jesus E Sanchez-Garavito
Molecular Therapy. Oncology. 2024-12-19
Abstracts/Posters
- A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...Mohamed A Kharfan-Dabaja, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Ly...Mohamed A Kharfan-Dabaja, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center f...Mohamed A Kharfan-Dabaja, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
Fighting Lymphoma: Treatment Options Include Alternatives to ChemotherapyJune 18th, 2024
Other Languages
- Arabic, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
